| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(13 days ago) | |
| US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(13 days ago) | |
Tyzeka is owned by Novartis.
Tyzeka contains Telbivudine.
Tyzeka has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Tyzeka are:
- US7858594
- US7589079
Tyzeka was authorised for market use on 28 April, 2009.
Tyzeka is available in solution;oral dosage forms.
Tyzeka can be used as treatment of chronic hepatitis b in adult patients.
The generics of Tyzeka are possible to be released after 11 September, 2023.
Drugs and Companies using TELBIVUDINE ingredient
Market Authorisation Date: 28 April, 2009
Treatment: Treatment of chronic hepatitis b in adult patients
Dosage: SOLUTION;ORAL
TYZEKA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic